Smith & Nephew heads into its May 6 Q1 trading update with short sellers retreating — but the borrow market tightening ahead of the release.
The short-side pressure has fallen sharply over the past month. Short interest dropped roughly 19% over 30 days to around 3.35 million shares, and declined another 11% on the week. That unwind is the headline move in the lending market. However, borrow availability has tightened in the other direction: the lending pool is approaching capacity, with availability now at its most constrained level in weeks after sitting at 100% utilisation as recently as late March. The cost to borrow has edged higher alongside that tightening, climbing to roughly 4.6% APR from below 2% just six weeks ago. Those two forces — fewer short positions but tighter borrow conditions — suggest the easy-entry window for new shorts has narrowed even as existing ones are being covered.
Options positioning confirms a cautious but not alarmed mood. The put/call ratio has drifted to 0.19, running about 2.4 standard deviations above its 20-day mean of 0.19 — a technically elevated reading, though still in deeply call-dominated territory. The PCR sits near its 52-week low end of the range, and the ORTEX short score has held steady around 52 for the past fortnight, ranking in just the 22nd percentile. The stock itself is down about 2% over the past month at $31.16, with a minor 1.3% slip on the week.
The analyst community has been cautious for some time, and the most recent move underlines that. Canaccord Genuity trimmed its price target on SNN to $34.75 in the run-up to results — a modest cut, but the firm stays at Hold. Bernstein downgraded the stock to Market Perform from Outperform back in October 2025, citing the persistent gap between Smith & Nephew's ROIC in orthopaedics and its higher-returning sports medicine and wound management divisions. The bull case centres on the 5.5% underlying growth in orthopaedics and the strong uptake of CORI robotic placements, which drove nearly 24% growth in Other Reconstruction. Bears point to Q1 headwinds from fewer selling days, ongoing China inventory digestion, and mounting pressure on US reimbursement rates. The consensus price target around $35 sits roughly 12% above the current price, suggesting the Street sees room for recovery but isn't in a rush to upgrade.
Institutional ownership tells a more constructive story than the analyst tone implies. Cevian Capital — an activist-leaning Swedish fund — holds 9.3% of shares, making it the single largest disclosed holder. BlackRock sits neck-and-neck at 9.3%. Both added materially in the most recent reporting period. Causeway Capital and RWC Partners each added more than 7 million ADR-equivalent shares. That cluster of active managers building positions alongside the activist presence suggests some confidence in a self-help narrative. The CEO also bought shares in November 2025, though the $600,000 purchase is now outside the 90-day window for near-term signal value.
The Q1 trading update is therefore less a test of whether the underlying business is recovering and more of whether management can demonstrate that China headwinds are fading and that the second-half margin improvement thesis remains intact given a softer revenue start to the year.
See the live data behind this article on ORTEX.
Open SNN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
